A new survey from Innovatix is highlighting concerns home infusion providers have as the 21st Cures Act enters its fifth month. Under the law, which was signed by President Barack Obama in December 2016, the payment structure for infusion drugs under Medicare Part B changed from an average wholesale price to an average sales price.
To compensate for this, the law includes a new Medicare payment for services that accompany home infusion treatments, but that doesn’t take effect until 2021, leaving 92% of home infusion providers surveyed saying they think the change to ASP will be damaging or severely damaging to their business. Thirty-one percent said the reimbursement change would likely push them to stop accepting new patients with Medicare benefits and 34% say they will be forced to discontinue home services for their existing patient population.
